Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 4, 2009, Pages 348-352

  Lee, Suee ^a   Oh, Sung Yong ^a   Kim, Byung Geun ^a   Kwon, Hyuk Chan ^a   Kim, Sung Hyun ^a   Rho, Myung Hwan ^a   Kim, Young Hoon ^a   Rho, Mee Sook ^a   Jeong, Jin Sook ^a   Kim, Hyo Jin ^a  

^a Dong A University College of Medicine   (South Korea)

Author keywords

5 fluorouracil; Adriamycin; Biliary tract cancer; Mitomycin C; Pancreatic cancer; Second line treatment

Indexed keywords

CISPLATIN; DOXORUBICIN; FLUOROURACIL; GEMCITABINE; MITOMYCIN C;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GALLBLADDER CANCER; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PANCREAS CANCER; PATIENT SAFETY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILIARY TRACT NEOPLASMS; CHI-SQUARE DISTRIBUTION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOMYCIN; NEOADJUVANT THERAPY; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROBABILITY; PROPORTIONAL HAZARDS MODELS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 69349104715     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31818c08ff     Document Type: Article

References (22)

1. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413. (Pubitemid 27251144)
2. Pasetto LM, D'Andrea MR, Falci C, et al. Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol Hematol. 2007;61:230-242. (Pubitemid 46343607)
3. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19:3447-3455. (Pubitemid 32730080)
4. Evans DB, Lee JE, Pisters PW, et al. Advances in the diagnosis and treatment of adenocarcinoma of the pancreas. Cancer Treat Res. 1997;90:109-125.
5. Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593-600. (Pubitemid 26285639)
6. Choi CW, Choi IK, Seo JH, et al. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. Am J Clin Oncol. 2000;23:425-428.
7. MacDonald JS, Woolley PV, Smythe T, et al. 5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer. 1979;44:42-47. (Pubitemid 9234907)
8. Smith FP, Hoth DF, Levin B, et al. 5-fluorouracil, adriamycin, and mitomycin- C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer. 1980;46:2014-2018. (Pubitemid 10025478)
9. Harvey JH, Smith FP, Schein PS. 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol. 1984;2:1245-1248.
10. Goldberg RM, Smith FP, Ueno W, et al. 5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. J Clin Oncol. 1986;4:395-399. (Pubitemid 16133093)
11. Kulke MH, Blaszkowsky LS, Ryan DP, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2007;25:4787-4792. (Pubitemid 350086482)
12. Boeck S, Weigang-Kohler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol. 2007;18:745-751. (Pubitemid 46523280)
13. Gebbia V, Maiello E, Giuliani F, et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol. 2007;18(suppl 6):vi124-vi127.
14. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer. 2006;94:481-485. (Pubitemid 43289750)
15. Reni M, Pasetto L, Aprile G, et al. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer. 2006;94:785-791.
16. Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs. 2005;23:369-375. (Pubitemid 40980360)
17. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology. 2004;67:93-97. (Pubitemid 39482675)
18. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer. 2003;88:1180-1184. (Pubitemid 36606330)
19. Tsavaris N, Kosmas C, Gouveris P, et al. Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004;22:193-198. (Pubitemid 38270476)
20. Carlson RW, Sikic BI. Continuous infusion or bolus injection in cancer chemotherapy. Ann Intern Med. 1983;99:823-833. (Pubitemid 14248413)
21. Seifert P, Baker LH, Reed ML, et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975;36:123-128.
22. Nakachi K, Furuse J, Ishii H, et al. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol. 2007;37:114-120. (Pubitemid 47090708)